CSTI-500
Phase 2Small molecule
CSTI-500 is one of 34 small molecule programs targeting Prader-Willi syndrome. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Prader-Willi Syndrome
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Topamax
WWim Janssens
Approved
Intuniv
PPromius Pharma, LLC
Approved
Growth Hormone
PfizerApproved
Wakix
HHarmony Biosciences Management, Inc.
Phase 3
Pabal
AACADIA Pharmaceuticals Inc.
Phase 3
Sandostatin LAR
NovartisPhase 3
Nutropin AQ
RochePhase 3
Rimonabant
SanofiPhase 3
Genotropin
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CSTI-500. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CConSynance Therapeutics